Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib targets the BCR‑ABL driven pathway in myeloid and lymphoid malignancies.

Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and helps achieve disease control. Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission and improves survival rates. Accelerated or blast phase CML: extends overall survival in advanced disease stages.

Common Side Effects: - Nausea - Diarrhea - Rash or skin irritation - Headache - Fatigue - Musculoskeletal pain

Serious or Rare Side Effects: - Cardiovascular events such as arterial occlusion or ischemic heart disease - Pancreatitis - Severe liver injury (hepatitis, elevated transaminases) - QT interval prolongation leading to arrhythmia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe infections requiring hospitalization

Before and during therapy, clinicians should monitor several safety parameters.

Monitor cardiac function: obtain baseline ECG and repeat periodically. Assess liver function: check transaminases before initiation and during treatment. Check pancreatic enzymes: monitor amylase and lipase for signs of pancreatitis. Evaluate QT interval: correct electrolyte disturbances and avoid concurrent QT‑prolonging drugs. Avoid use in pregnancy: drug is classified as Category D and should not be used unless benefits outweigh risks. Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Nilotinib has several clinically significant drug interactions that require careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may raise plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy. - Antacids containing aluminum or magnesium – can impair absorption. - QT‑prolonging agents (e.g., sotalol, amiodarone) – increase risk of arrhythmia. - Concomitant warfarin – may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin). - Moderate CYP3A4 inducers (e.g., phenytoin, phenobarbital). - H2‑blockers (e.g., ranitidine, famotidine) – may modestly affect bioavailability. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin) – consider dose adjustment. - Diuretics causing electrolyte shifts – monitor potassium and magnesium to prevent QT prolongation.